Cited 0 times in
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.